TrialPloS one2018

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design.

Edna O Viegas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.